Adaptimmune has become one of the first firms to have a drug accepted into EMA’s PRIME regulatory fast-track initiative.

Pfizer has secured an exclusive option to acquire Western Oncolytics’ WO-12 once the oncolytic vaccinia virus has completed Phase I.

Celgene highlighted a handful of immuno-oncology deals that are driving its long-term R&D prospects including Juno and bluebird CAR-T partnerships.

Intermountain Healthcare is back at it, this time tackling Type 2 diabetes. The company has partnered with the American Medical Association and Omada Health to…

Should it stay or should it IPO? That’s the question facing inVentiv owner Thomas H. Lee Partners as it weighs up potential bids from two buyout firms--while…

Shares in uniQure briefly hit a new low following a negative knee-jerk reaction to fresh data on its hemophilia B gene therapy.

Specialty pharma InnoPharma was acquired by Pfizer a few years ago for up to $360 million. Now, the team behind that effort is at it again with another…

GlaxoSmithKline will pay up to £175 million ($230 million) to gain global, exclusive rights to a Phase I monoclonal antibody to treat severe asthma from…